Females must not be pregnant or lactating. Women of child-bearing potential must use a highly effective method of contraception throughout their study participation and for at least  months following the last dose of study drug.
Women of child-bearing potential, unless they are using highly effective methods of contraception during dosing and for  weeks after study drug discontinuation
Women of childbearing potential (defined as all women physiologically capable of becoming pregnant) must agree to both of the following:\r\n* Use highly effective methods of contraception for at least  months after the last dose of huJCAR, and\r\n* Have a negative serum pregnancy test performed within  days before starting lymphodepleting chemotherapy
Women of child-bearing potential, defined as all women older than age  and anovulatory for  months, unless they are using highly effective methods of contraception during dosing and for  days after study treatment
Women of reproductive potential (defined as all women physiologically capable of becoming pregnant) must agree to use suitable methods of contraception for  days after the last dose of study therapy (durvalumab or JCAR)
Meets one of the following criteria: Is post-menopausal, or, Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and for four months after stopping medication.
Women of child-bearing potential must have negative serum pregnancy test and use accepted highly effective methods of birth control throughout the study and for  days after dosing and must agree to use effective contraception.
Women of child-bearing potential, unless they are using highly effective methods of contraception
Women of child-bearing potential (WOCBP), defined as all women physiologically capable of becoming pregnant, must use highly effective methods of contraception during the study and  weeks after; highly effective contraception methods include combination of any two of those listed in the protocol
Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, must use  highly effective methods of contraception while taking study treatment and for  days after the last dose of study treatment.
Women of child bearing potential who refuse or are not able to use a highly effective method of contraception as defined in the study protocol.
Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and for  months after pasireotide s.c. last dose and  months after pasireotide LAR last dose Highly effective contraception methods include:
Women of child-bearing potential who are sexually active with a non-sterilized male partner, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective contraception from screening throughout study treatment, and must agree to continue using such precautions for  months after the final dose of investigational product; cessation of birth control after this point should be discussed with a responsible physician. Highly effective methods include the following:
Women of child-bearing potential (WOCBP), defined as all women physiologically capable of becoming pregnant, must use highly effective methods of contraception during the study and  weeks after; highly effective contraception methods include combination of any two of the following:
Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and for  months afer stopping ceritinib treatment.
Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during the study and for  days after the final dose of imatinib. Male patients must use highly effective contraception during the study and for  days after the final dose of imatinib. Highly effective contraception is defined as either:
Women of child-bearing potential defined as all women physiologically capable of becoming pregnant who are unwilling to use highly effective methods of contraception throughout the study and  days after study drug discontinuation
Women of childbearing potential must use highly effective methods of contraception throughout the study and for  months after study drug discontinuation
Women of child-bearing potential unless they are using highly effective methods of contraception during the study treatment and for  days after stopping the study treatment.
Women of child-bearing potential (defined as all women physiologically capable of becoming pregnant) and all male participants must agree to use highly effective methods of contraception for at least  months following CTL infusion and until CAR T cells are no longer present by PCR on two consecutive tests
Women of child-bearing potential (defined as all women physiologically capable of becoming pregnant) and all male participants, unless they are using highly effective methods of contraception for a period of  year after the CTL infusion.
SUB-PROTOCOL AIM A: Any of the following:\r\n* Pregnant women\r\n* Nursing women\r\n* Women of child-bearing potential, who are biologically able to conceive, or men who are able to father a child, not employing two forms of highly effective contraception\r\n** Highly effective contraception (e.g., male condom with spermicide, diaphragm with spermicide, intra-uterine device, and total abstinence) must be used by both sexes during the study and must be continued for  months after the end of study treatment; Note: Oral, implantable, or injectable hormone contraceptives are not considered effective for this study
Patient is pregnant or nursing or physiologically capable of becoming pregnant and not using highly effective contraception
Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and for  week after completion of dosing.
Surgically sterile patients or patients of child-bearing potential who agree to use highly effective methods of contraception during study dosing and for  months after last dose of study drug
Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and for  months after treatment completion
Women of child-bearing potential, unless they are using highly effective methods of contraception during dosing and for  weeks after study drug discontinuation
Women of child-bearing potential must use highly effective contraception during the study and for  days after the study drug infusion.
Women of child-bearing potential unless they are using highly effective methods of contraception during the dosing and for at least  hours after last dose. Highly effective contraception as defined in the protocol.
Pregnant and nursing women, or women planning to become pregnant within  months after the end of treatment, are excluded from this study; a negative pregnancy test will be required of women of child-bearing age within  hours of study enrollment; subjects (male or female) who are not willing to use highly effective methods of contraception (per institutional standard) during treatment and for  months (male or female) after the end of treatment are excluded
Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and for  days after stopping study medication. Highly effective contraception methods include:
Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception throughout the study and for  months after study drug discontinuation; highly effective methods of contraception are further defined
Pregnant or nursing (lactating) women confirmed by a positive hCG laboratory test\r\n* Women of child-bearing potential unless they are using highly effective methods of contraception throughout the study and for  days after study drug discontinuation
Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception throughout the study for  days after study drug discontinuation
Women of child-bearing potential unless they are using highly effective methods of contraception during the study treatment and for  days after stopping the study treatment.
Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during the study and for  days after the final dose of nilotinib. Highly effective contraception is defined as either:
